Tier 2 — strong

Effects of Quercetin on Adiponectin-Mediated Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Double-Blind Clinical Trial

N Rezvan, A Moini, L Janani, K Mohammad, A Saedisomeolia, M Nourbakhsh, S Gorgani-Firuzjaee, M Mazaherioun, M J Hosseinzadeh-Attar
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2017 49(2):115

Bibliography

PubMed
PMID 27824398
DOI
10.1055/s-0042-118705
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled PCOS trial
ModelHuman intervention research
Sample84 women with PCOS
InterventionQuercetin 1,000 mg/day versus placebo
Duration12 weeks
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2017, this source examined hormones and reproductive health. Design: Randomized double-blind placebo-controlled PCOS trial. Sample/model: 84 women with PCOS. The exposure or intervention was Quercetin 1,000 mg/day versus placebo. Follow-up or treatment period: 12 weeks.

Adiponectin measures increased and HOMA-IR, testosterone and LH decreased relative to placebo.

Short disease-specific study. Companion receptor-expression reporting belongs to the same registered trial, not a separate replication.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Benefits: What Human Studies Actually Show. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Adiponectin measures increased and HOMA-IR, testosterone and LH decreased relative to placebo.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Quercetin 1,000 mg/day versus placebo; 12 weeks.

What this study can and cannot tell us

  • Short disease-specific study. Companion receptor-expression reporting belongs to the same registered trial, not a separate replication.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Oral Quercetin Supplementation Enhances Adiponectin Receptor Transcript Expression in Polycystic Ovary Syndrome Patients: A Randomized Placebo-Controlled Double-Blind Clinical Trial
Neda Rezvan et al. · Cell journal · 2018
Tier 2
Quercetin and polycystic ovary syndrome; inflammation, hormonal parameters and pregnancy outcome: A randomized clinical trial
Sima Vaez et al. · American journal of reproductive immunology (New York, N.Y. : 1989) · 2023
Tier 2
The effects of quercetin supplementation on metabolic and hormonal parameters as well as plasma concentration and gene expression of resistin in overweight or obese women with polycystic ovary syndrome
Masoud Khorshidi et al. · Phytotherapy research : PTR · 2018

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology